NeuroSense Therapeutics has enrolled and dosed the first healthy subject in the pharmacokinetic (PK) study of its combination drug candidate, PrimeC, to treat amyotrophic lateral sclerosis (ALS). PrimeC comprises a fixed-dose mixture of ciprofloxacin and celecoxib, which are approved by the US Food and Drug Administration (FDA).

The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest in life science licensing and collaboration deals. Telix Pharmaceuticals and Eli Lilly Telix Pharmaceuticals signed a license agreement with Eli Lilly and Company, granting Telix exclusive global rights to develop […]

Checkpoint inhibitors offer significant improvements in cancer care, yet even in combination with other checkpoint inhibitors or monoclonal antibodies, their results remain unsatisfactory for many. As Daniel Teper, CEO of Cytovia Therapeutics pointed out, “The best standard of care for advanced hepatocellular carcinoma (HCC) – a combination of atezolizumab (anti-PDL1 antibody) and bevacizumab (anti-VEGF antibody) – offers less […]